MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

MERTK

  • Home
  • MERTK
Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance
Posted inHematology-Oncology news

Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

Posted by By MedXY 09/28/2026
Aberrant MERTK expression activates BCR signaling via CD79a in CLL, offering a novel therapeutic target. Inhibiting MERTK with UNC-2025 shows potential against ibrutinib-resistant relapse, especially combined with venetoclax.
Read More
  • Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets
  • Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance
  • Recombinant ADAMTS13 Therapy Demonstrates Superior Efficacy and Safety Over Plasma-Based Therapy in Congenital Thrombotic Thrombocytopenic Purpura: Final Phase 3 Trial Results
  • Plasma sRAGE Biomarker Guides Personalized Lung Recruitment Strategies in ARDS: Insights from the LIVE Trial
  • Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top